Clinical trial
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
NCT00413036 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00413036 |
|---|---|
| Title | A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma |
| Official title | A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | lenalidomide |
| Enrollment | 217 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Dec 19, 2006 |
| Last update posted | Mar 1, 2017 |
| Countries | Canada, France, Germany, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: